Home > Investor Relations
Achilllion is focused on transforming innovation into novel therapies to address patient needs.
The investor pages that follow are your resource for financial information about Achillion Pharmaceuticals. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.
Aug 10, 2015
Aug 3, 2015
Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics